20n
20n is a YC Winter 2015 (W15) company. Based in San Francisco, CA, USA. Team of 2.
About 20n
Summary
20n builds computational systems that predict DNA design for industrial biotech and therapeutic applications. Its platform applies machine learning, AI planning, and data mining to biological data, helping biotech firms engineer organisms for manufacturing fuels, materials, flavors, fragrances, and drug candidates. It replaces manual, trial-and-error approaches to metabolic pathway design, letting customers enter markets previously out of reach for biological processes.
Go-to-market
Industrial biotech firms are the primary customers, engaging 20n to solve DNA design problems that their own computational capabilities cannot address.
From the Y Combinator listing
Using AI to predict biochemistry for manufacturing and therapeutics
The next decade is going to see a biotech revolution fueled by three technologies: ability to read DNA (sequencing), ability to write DNA (synthesis), and computational systems that predict what DNA to read and write. With sequencing and synthesis being mainstream now [1], 20n provides the computational systems that predict DNA design for novel industrial biotech and health applications. At 20n, we are taking a fresh look at turning biological data into information. We approach it as a big data learning problem, and bring to bear techniques from machine learning, distributed systems, AI planning, program synthesis, data mining, and natural language processing. With the support of DARPA [2], we are building a team of computer scientists, and bioengineers to look at biology in fundamentally new ways. Our current customers include industrial biotech firms that are leading the charge in transitioning us from traditional unsustainable means of manufacturing to sustainable biological processes leading to advanced fuels, materials, therapeutics, and flavors and fragrances. 20n’s technology helps them enter markets previously thought inaccessible for biology. [1] Sequencing DNA costs $4k/genome (http://www.genome.gov/sequencingcosts/) and is expected to go down to $1k/genome. Synthesizing DNA is at 20cents/bp, and is expected to go down to 0.1cents/bp. [2] DARPA in the past supported work that led to the internet, stealth planes, GPS, and even Douglas Engelbart’s mother-of-all-demos.
Facts
- Healthcare / Healthcare -> Industrial Bio
- San Francisco, CA, USA
- 2
- Inactive
- Early
Founders (2)
- Chris Anderson
- Saurabh Srivastava
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works